Gilead Sciences (GILD) is a biopharmaceutical company that makes treatments for HIV, hepatitis, and cancer. Over the past year, the stock has traded in an upward, parallel channel. It moved from the low $60s in early 2024 to near $150.
The channel has produced a pattern of higher lows and higher highs. The lower trendline has acted as support on multiple tests, while the upper trendline has acted as resistance.
In late January 2026, the stock surged and hit the upper boundary near $157–158. Since then, it has pulled back to $149.83.
The channel’s midline is projected near $136–140 and could act as support if the decline continues. Another key area to watch is $140–144.
The lower channel support line is now rising through the low $120s. A close below that area would signal a break below the channel.
The upper channel resistance remains near $160. If the channel stays intact and continues to rise in 2026, price targets would also move higher.
The pullback in Gilead Sciences from the upper channel area near $158 is not surprising after last month’s strong rally. That rally followed the late January earnings report for Q4 2025. The report showed Trodelvy sales beat expectations, rising 38% year over year. The stock is now working off those gains, which is often a healthy part of an ongoing uptrend.
If you expect the channel to hold, this dip may offer a chance to prepare for another move higher. One approach is buying April $155 calls to target a retest of the recent highs, especially if the stock stabilizes in the $140–144 zone. This trade works best if the rebound happens quickly.
A more conservative alternative is selling put spreads below the current price. This strategy benefits if the stock stays above a chosen level. Selling a March or April $140/$135 put spread fits with the channel’s midline support area. It can also benefit from time decay, and implied volatility may still be elevated after last month’s earnings.
The strong rejection at the channel top also shows sellers are active. If you expect a deeper drop toward the $136–140 midline, you could consider buying March $145 puts. This offers defined risk if the pullback accelerates.
Another way to trade the overhead resistance is selling a bear call spread, such as the March $155/$160. This position assumes GILD will not make a new high in the near term. It can profit if the stock moves sideways or down, using the resistance above as a cushion. A similar consolidation happened in Q3 2025 before the next leg higher began.
here to set up a live account on VT Markets now
